Retinal Vein Occlusion Treatment Market Report 2026

Retinal Vein Occlusion Treatment Market Overview

• Retinal Vein Occlusion Treatment market size has reached to $2.42 billion in 2025 • Expected to grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: The Growing Impact Of Eye Diseases On The Treatment Market • Market Trend: Innovations In Retinal Vein Occlusion Treatment To Focus On Interchangeable Biosimilars • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Retinal Vein Occlusion Treatment Market?

Retinal vein occlusion (RVO) treatment involves various strategies aimed at managing complications caused by blocked blood vessels in the retina. These treatments typically focus on reducing swelling (edema) and preventing further vision loss. The main diseases for retinal vein occlusion treatment are central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Central retinal vein occlusion (CRVO) refers to a blockage of the central vein in the retina, leading to vision loss due to impaired blood flow and potential retinal damage. Diagnosis often involves optical coherence tomography, fundoscopic examination, and fluorescein angiography. Treatments may include anti-vascular endothelial growth factor (Anti-VEGF) agents, corticosteroid drugs, and others. These treatments are utilized by end users such as hospitals, clinics, research institutions, academic facilities, and others.

What Is The Retinal Vein Occlusion Treatment Market Growth Forecast?

The retinal vein occlusion treatment market size is expected to see strong growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing demand for durable treatment outcomes, rising investments in novel drug delivery systems, expansion of biosimilar adoption, growing focus on patient-centric treatment models, increasing use of real-world evidence in therapy selection. Major trends in the forecast period include increasing use of combination drug therapies, rising adoption of long-acting injectables, growing integration of precision diagnostics, expansion of personalized treatment protocols, enhanced focus on visual acuity preservation.

Global Retinal Vein Occlusion Treatment Market Segmentation

1) By Disease Type: Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO) 2) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography 3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments 4) By End-User: Hospital And Clinics, Research And Academics, Other End-Users Subsegments: 1) By Central Retinal Vein Occlusion (CRVO): Non-Ischemic CRVO, Ischemic CRVO 2) By Branch Retinal Vein Occlusion (BRVO): Non-Ischemic BRVO, Ischemic BRVO

What Is The Driver Of The Retinal Vein Occlusion Treatment Market?

The increasing prevalence of eye conditions is expected to propel the growth of the retinal vein occlusion treatment market going forward. Eye conditions refer to any disorders or diseases affecting the eyes or vision. They can include a range of issues, from minor irritations and infections to more serious conditions like glaucoma, cataracts, macular degeneration, and diabetic retinopathy. The rise in cases of eye conditions is attributed to factors such as aging populations and the increasing prevalence of diabetes and hypertension. Retinal vein occlusion treatment aims to restore blood flow and reduce inflammation to prevent vision loss and manage complications associated with this eye condition. For instance, in January 2024, according to the Centers for Disease Control and Prevention, a US-based science and data-driven service organization that protects the public's health, over 3.4 million Americans aged 40 years and older were blind or visually impaired, which is expected to double by 2030. Therefore, the increasing prevalence of eye conditions is driving the growth of the retinal vein occlusion treatment industry.

Key Players In The Global Retinal Vein Occlusion Treatment Market

Major companies operating in the retinal vein occlusion treatment market are Roche Holding AG, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Chengdu Kanghong Pharmaceutical Group Co Ltd, Genentech Inc, Apellis Pharmaceuticals Inc, Alimera Sciences Inc, Ocular Therapeutix Inc, EyePoint Pharmaceuticals Inc, Aerpio Pharmaceuticals Inc, REGENXBIO Inc, Adverum Biotechnologies Inc, Graybug Vision Inc, Oxurion NV, PanOptica Inc, Clearside Biomedical Inc, Kodiak Sciences Inc, Outlook Therapeutics Inc, Annexin Pharmaceuticals AB

Global Retinal Vein Occlusion Treatment Market Trends and Insights

Major companies operating in the retinal vein occlusion treatment market are focusing on developing innovative products, such as interchangeable biosimilars, to enhance treatment options and improve patient accessibility. An interchangeable biosimilar is a biologic drug that is highly similar to an existing reference biologic and can be used as an alternative to manage inflammation and fluid leakage effectively. For instance, in May 2024, Biocon Biologics Limited, an India-based biosimilar manufacturing company, received US Food and Drug Administration approval for Yesafili (aflibercept-jbvf), which is an interchangeable biosimilar of EYLEA (aflibercept). It functions as a vascular endothelial growth factor (VEGF) inhibitor, treating various ophthalmic conditions such as neovascular age-related macular degeneration (wet AMD), macular edema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV).

What Are Latest Mergers And Acquisitions In The Retinal Vein Occlusion Treatment Market?

In December 2024, Regeneron Pharmaceuticals, a U.S.-based provider of innovative biologic therapies and advanced ophthalmology treatments, acquired Oxular Limited for an undisclosed amount. With this acquisition, Regeneron aims to expand its retinal disease pipeline and strengthen its technological capabilities by integrating Oxular’s sustained-delivery therapeutic platform for conditions such as diabetic macular oedema, retinal vein occlusion, and uveitis. Oxular Limited is a UK-based provider of long-acting ophthalmic drug candidates and proprietary suprachoroidal delivery systems designed to improve durability and outcomes in posterior-segment eye diseases.

Regional Outlook

North America was the largest region in the retinal vein occlusion treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Retinal Vein Occlusion Treatment Market?

The retinal vein occlusion treatment market consists of revenues earned by entities by providing services such as laser therapy, medication administration, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinal vein occlusion treatment market also includes sales of vitrectomy equipment, and optical coherence tomography (OCT) devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Retinal Vein Occlusion Treatment Market Report 2026?

The retinal vein occlusion treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the retinal vein occlusion treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.